We are live on ! Find out more
Renaissance Technologies

Renaissance Technologies Portfolio holdings

AUM $63.9B
1-Year Est. Return 45.56%
 

Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.

This Fund
S&P 500
This Quarter Est. Return
-13.57%
1 Year Est. Return
+45.56%
3 Year Est. Return
+129.95%
5 Year Est. Return
+153.6%
10 Year Est. Return
+738.07%
AUM
$84.5B
AUM Growth
-$745M
Cap. Flow
+$13.7B
Cap. Flow %
16.26%
Top 10 Hldgs %
10.97%
Holding
4,738
New
695
Increased
1,955
Reduced
1,481
Closed
562

Sector Composition

Rank Sector Weight
1 Healthcare 19.41%
2 Technology 16.8%
3 Consumer Staples 11.12%
4 Consumer Discretionary 10.11%
5 Financials 8.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
WNW icon
4001
Meiwu Technology Co
WNW
$3.33M
$48K ﹤0.01%
+1
New +$47.4K
ELOX
4002
DELISTED
Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
$48K ﹤0.01%
+4,485
New +$61.9K
BCLI
4003
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$47K ﹤0.01%
+1,140
New +$51.3K
TOVX icon
4004
Theriva Biologics
TOVX
$9.64M
$47K ﹤0.01%
876
+446
+104% +$25.5K
SNAX
4005
DELISTED
Stryve Foods, Inc. Class A Common Stock
SNAX
$47K ﹤0.01%
3,533
+1,820
+106% +$29.6K
CRXT
4006
DELISTED
Clarus Therapeutics Holdings, Inc. Common Stock
CRXT
$47K ﹤0.01%
122,277
+87,577
+252% +$61.3K
AKTX
4007
Akari Therapeutics
AKTX
$13.8M
$46K ﹤0.01%
57
-1
-2% -$887
BINI
4008
DELISTED
Bollinger Innovations
BINI
0
TWAV
4009
TaoWeave Inc
TWAV
$4.49M
$46K ﹤0.01%
245
-102
-29% -$25.4K
QNTM
4010
Quantum Biopharma Class B Subordinate Voting Shares
QNTM
$18.5M
$46K ﹤0.01%
905
+403
+80% +$24.2K
EVK
4011
DELISTED
Ever-Glory International Group, Inc.
EVK
$46K ﹤0.01%
34,900
-1,100
-3% -$1.54K
ADAG
4012
Adagene
ADAG
$248M
$45K ﹤0.01%
+21,794
New +$65.9K
RMTI icon
4013
Rockwell Medical
RMTI
$28.4M
$45K ﹤0.01%
3,502
+945
+37% +$25K
UCL
4014
uCloudlink Group
UCL
$33.1M
$45K ﹤0.01%
40,005
+7,205
+22% +$8.53K
MOHO
4015
DELISTED
ECMOHO Limited American Depositary Shares
MOHO
$45K ﹤0.01%
276,707
-16,700
-6% -$3.32K
NMAD
4016
Nomad Power Solutions
NMAD
$81.9M
$43K ﹤0.01%
+5,719
New +$58.3K
ALAR
4017
Alarum Technologies
ALAR
$12.3M
$42K ﹤0.01%
8,602
+4,302
+100% +$25.3K
LGMK
4018
DELISTED
LogicMark
LGMK
$42K ﹤0.01%
+78
New +$58.1K
ORC
4019
Orchid Island Capital
ORC
$1.3B
$42K ﹤0.01%
+2,920
New +$43.4K
EFTR
4020
DELISTED
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
$42K ﹤0.01%
+1,172
New +$70.9K
AVGR
4021
DELISTED
Avinger, Inc. Common Stock
AVGR
$42K ﹤0.01%
+1,931
New +$64K
AYLA
4022
DELISTED
Ayala Pharmaceuticals, Inc. Common Stock
AYLA
$42K ﹤0.01%
+38,101
New +$87K
DS
4023
DELISTED
Drive Shack Inc.
DS
$42K ﹤0.01%
30,328
-520,672
-94% -$742K
CRTD
4024
DELISTED
Creatd Inc. Common Stock
CRTD
$42K ﹤0.01%
+57,494
New +$53.1K
ATXS
4025
DELISTED
Astria Therapeutics
ATXS
$41K ﹤0.01%
+13,700
New +$61.4K

Similar funds

Renaissance Technologies's Q2 2022 Portfolio in Review

As of Q2 2022, Renaissance Technologies held 4,738 positions worth $84.5B, down 0.87% from $85.2B the previous quarter. Its ten largest holdings account for 11% of the portfolio.

Renaissance Technologies deployed $13.7B of net new capital in Q2 2022, opening 695 new positions and adding to 1,955 existing holdings. Its largest new stake was Microsoft: 3,820,133 shares worth $981M.

By sector, the portfolio is most concentrated in Healthcare at 19% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Staples.

On the sell side, the largest reduction was Tesla, an estimated $661M trimmed.

  • Renaissance Technologies's largest Q2 2022 buy was Microsoft: 3,820,133 shares worth $981M.
  • Renaissance Technologies added most to Chevron in Q2 2022, an estimated $820M increase.
  • Renaissance Technologies's biggest Q2 2022 reduction was Tesla, cutting an estimated $661M.
  • Renaissance Technologies fully exited Amazon in Q2 2022, selling an estimated $675M.
  • Renaissance Technologies's ten largest holdings make up 11% of its $84.5B portfolio in Q2 2022.
  • Renaissance Technologies opened 695 new positions and closed 562 in Q2 2022.
  • Renaissance Technologies's portfolio value fell 0.87% quarter-over-quarter to $84.5B.

Based on Renaissance Technologies's 13F filing for Q2 2022, filed 12 Aug 2022.